On May 18-20, Insmed provided more positive supporting data on both NTM and CF yet the PPS is $12.26:
May 14, 2014 15.16 15.80 14.78 14.83 457,400 14.83
May 13, 2014 15.61 15.91 14.92 15.26 543,700 15.26
May 12, 2014 14.49 15.85 14.47 15.73 809,200 15.73
May 09, 2014 13.75 14.53 13.19 14.46 474,500 14.46 (see below's PR)
May 08, 2014 13.78 15.32 13.68 13.71 927,800 13.71
Insmed Incorporated (INSM)
May 09, 2014
Chief Pulse Comment by William H Lewis
MONMOUTH JUNCTION, NJ ( Marketwired , May 08, 2014) , Insmed Incorporated ( NASDAQ: INSM ) today reported financial results for the three months ended March 31, 2014. Highlights of the first quarter of 2014 and recent weeks include: Announced top line clinical results from a phase 2 clinical study of ARIKAYCE™, or liposomal amikacin for inhalation, for the treatment of patients with treatment resistant nontuberculous mycobacterial ( NTM) lung infections;
Applied for Breakthrough Therapy Designation in the United States for ARIKAYCE to treat NTM lung infections; Reported positive interim data from the two year, open label extension study of ARIKAYCE to treat Pseudomonas aeruginosa infections in cystic fibrosis ( CF) patients, which demonstrated long term safety and durability of effect at 12 months;
Entered into a contract manufacturing agreement with Therapure Biopharma Inc for the manufacture of ARIKAYCE; and Received Orphan Medical Product Designation in the European Union for ARIKAYCE to treat lung infections caused by NTM. "We remain on track to discuss our recent clinical results with the U. S. Food and Drug Administration and the European Medicines Agency to determine next steps for ARIKAYCE," said Will Lewis, President and Chief Executive Officer of Insmed.
"We look forward to the presentations of ARIKAYCE data at the American Thoracic Society's Annual Meeting later this month. The presentation of the NTM data will include data from the three month, open label portion of the study."